Stop taking everything viTelInA says so seriouslyTo invest in this company is a big risk, even with any of the companies in this industry. There is no possible way vitelina has some secret information on Mydecine. Why would the company give someone information to someone that has no relationship to the company other than owns shares. I would understand if he knew someone from the company and they had told him but I doubt it. Stop relying on vitelina for advice or information in this message board.
Now looking at Mydecine, I strongly believe the share price will head north but it will be mainly on momentum of the industry and more exposure. Once other states start decriminalizing psychedelics or legalizing substances or when Health Canada sees positive results on trials, then I believe the share price will go up. I'm glad they are assisting with PTSD because if these mushrooms do help individuals with PTSD, the MYCO will benefit.
Also, remember that Mydecine announced they have licensed to produce and sell naturally-extracted psilocybin which is how they increase revenues. This will assist with the share price once psychedelics are proven to assist with mental health.
As for the Nasdaq listing... I've read through the requirements, read their financial statements for 2020 and it seems very unlikely. The only option would be having their share price reach at least $4 (you can have exceptions with $2or$3 as well). MYCO must also meet one of the four requirements: 1. Earnings cannot have a net lost in the past 3 years (MYCO has suffered a loss in each of the three years ... so this one is a NO) 2. Capitalization With Cash Flow (MYCO has had a negative cashflow... this one is also a NO) 3. Capitalization with Revenue (MYCO has to have a market cap of 850million for the past 12 months along with 90 mill in revenue in the prior fiscal year... so this is a NO) 4. Assets with Equity (MYCO must have a market cap of at least 160mill, total assets equal to at least 80mill and shareholders equity at least 55mill. This way is possible if MYCO can get their share price up and somehow invest more into R&D which will increase their assets because this would be a future economic benefit. (Reverse stock split sure but they would still need to increase their market cap).
Overall MYCO has a long way to go and the only way I'm in this company is because the potential for the share price to reach $1 +. Another reason I'm into this company is because I believe when Newleaf brands acquired Mydecine and Neuropharm, they took a step further in the battle of mental health. More exposure of MYCO will help the stock, for this I mean have it listed on the NEO. The high amount of shares outstanding does not help with the share price but for the company to raise capital and increase their R&D, this is what they must do. Momentum in the industry will help the share price a lot. Also, I’ve invested in SZLS or StageZero Life Sciences Ltd because of their new technology and revenue growth due to testing.